(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with Anochlesia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cano, C; Girón, R; Goya, P; Martín, MI; Paez, JA; Sánchez, E | 1 |
1 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and Anochlesia
| Article | Year |
|---|---|
Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity.
Topics: Animals; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Catalepsy; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Hypothermia; Injections, Intraperitoneal; Locomotion; Male; Mice; Mice, Inbred ICR; Molecular Structure; Morpholines; Naphthalenes; Pain Measurement; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Stereoisomerism; Thiadiazines; Vas Deferens | 2007 |